France has initiated steps to classify bisphenol B as an endocrine disruptor

Edited on 11/14/2019
Based on the results of its recent study on bisphenol B, ANSES has carried out a project of Risk Management Options Analysis (RMOA) in order to classify this substance as an endocrine disruptor under the REACH Regulation.
News text: 

As part of the National Strategy on Endocrine Disrupters (SNPE) ANSES studied the endocrine disrupting properties of bisphenol B (BPB), a substitute for certain uses of bisphenol A (including coatings and polymers in contact with food) used in some countries such as the United States. The conclusion of this work was that the BPB would have endocrine disrupting properties similar to those of BPA. Despite no production or use as a chemical substance in Europe, exposure to BPB is possible via imported products.

It is in this context that ANSES carried out a project of RMOA of the BPB in order to identify this substance as an endocrine disruptor in the REACH Regulation. This could represent a first step towards a possible addition of BPB to the list of candidate substances in Annex XIV of the REACH Regulation, thus preventing industry from developing its use or production to replace BPA or bisphenol S and imposing an authorization to place articles containing BPB on the market of the European Union (regarding uses targeted by the REACH Regulation).

The public consultation on the draft RMOA for bisphenol B is open until November 27, 2019.

Sources : (in French)

The publication of this information doesn't mean that INERIS approves it.